ClinicalTrials.gg
CompletedNCT06758661Updated May 21, 2025

Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers

A Phase 1 interventional study of D352 and D794 in Dyslipidemia, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 43 studies in Dyslipidemias by Chong Kun Dang Pharmaceutical — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Chong Kun Dang Pharmaceutical.

Enrollment
28th of 43
40 · median 48
Started
2024
with 1 other
Phase 1
38 of 43
none open now
Registered
43rd of 43
by date

Among the 43 studies in Dyslipidemias by Chong Kun Dang Pharmaceutical, this one is the 28th largest by enrollment, is one of 2 that started in 2024, is one of 38 in phase 1, and was the 43rd registered.

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 43 studies in Dyslipidemias by Chong Kun Dang Pharmaceutical is open now. The open studies under Dyslipidemias, anywhere →

Where they have run

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies in Dyslipidemias by Chong Kun Dang Pharmaceutical as a file.
02

Study summary

This study is a randomized, open-label, single arm, multi-dose, crossover study to evaluate drug-drug interaction and safety after co-administration of D352 and D794 in healthy adult volunteers.

Read the detailed description

36 healthy subjects are administration of D352 and D794 following each part. Pharmacokinetic blood samples are collected 1d to 22d. The drug-drug interaction and safety are assessed.

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult volunteers between the ages of 19 years to 55 years.
  2. Individuals who had 18 kg/m2 ≤ (BMI) \< 30 kg/m2 and total body weight ≥ 55 kg (woman total body weight ≥ 45 kg) BMI = Weight(kg)/ Height(m)2
  3. Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination
  4. Individuals who were deemed to be appropriate as study subjects following vital sign, laboratory tests (hematology, blood chemistry, serology, urology etc.) etc. performed
  5. Individuals who agreed proper during the study and did consent to not donation of sperm or eggs 14 days after the last dose of study drug
  6. Individuals who signed an form after being fully informed of the study prior to participation, including the objective, content, adverse events etc.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with a history of to any of the major ingredients or components of the product
  2. Individuals who have genetic problems such as galactose intolerance, Lap lactase deficiency, or glucose-galactose malabsorption
  3. Individuals who have a history of hypersensitivity or allergy to this ingredient because it contains Sunset Yellow FCF
  4. Patients with the following diseases

    • Patients with active liver disease or persistently elevated aminotransferase levels of unknown cause
    • Patients with severe hepatic impairment of biliary obstruction and patients with cholestasis
    • Patients receiving cyclosporine
    • Myopathic patients
  5. Individuals with a history of gastrointestinal surgery or gastrointestinal disease that may affect drug absorption
  6. Individuals who exceed the following condition with 1 month of the first administration of investigational product

    • Alcohol: Man-21 glasses/week, Woman-14 glasses/week (1 glass = soju 50mL or liquor 30mL or beer 250mL)
    • Smoking: 20 cigarettes/day
  7. Individuals who cannot restrict the intake of grapefruit or food containing grapefruit from three days before the first administration of investigational product until the final pharmacokinetic blood sample is collected
  8. Individuals who have used drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first dosing administration
  9. Individuals who have taken any specialty or herbal medicine within 2 weeks prior to the first administration, or any over-the-counter(OTC) or dietary supplement or vitamin preparation, including liver function supplements, within 1 week prior to the first administration
  10. Individuals with a history of substance abuse or test positive for drugs of abuse on a urine screening test
  11. Individuals who had been administered investigational product from other clinical study within the 6 months prior to the first administration
  12. Individuals who donated whole blood within the 8 weeks, or blood components within 2 weeks or had a blood transfusion within 4 weeks prior to the first administration of investigational product
  13. Woman who are pregnant or breastfeeding
  14. Individuals who have difficulty abstaining from omega-3-containing foods(such as oily fish, chia seeds, flaxseeds, walnuts, etc.) from 7 days before the first administration until the end of study
  15. Individuals who determines that the tester is unfit to participate in the clinical trial in the final inclusion/exclusion criteria determined by combining the results of the clinical laboratory test conducted on the hospitalization date(-7D)
  16. Those who are deemed insufficient to participate in this clinical study by investigators
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    D352-D352+D794(Part 1)

    Period 1: D352 1 tablet for 1 week, Period 2: D352 1 tablet and D794 4 capsule for 2 weeks

    Drug: D352 · Drug: D794

  • Experimental
    D794-D352+D794(Part 2)

    Period 1: D794 4 capsule for 2 weeks, Period 2: D352 1 tablet and D794 4 capsule for 1 week

    Drug: D352 · Drug: D794

Interventions

  • DrugD352

    1 tablet

  • DrugD794

    4 capsule

06

What researchers measure

Primary outcomes

  1. AUCtau,ss of D352(Part 1)

    Area under the D352 concentration in blood-time curve in steady-state

    Time frame: 1~7day 0 hour, 7day 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hour, 19~21day 0 hour, 21day 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hour

  2. AUCtau,ss of D794(Part 2)

    Area under the D794 concentration in blood-time curve in steady-state

    Time frame: 1day -24 hour~-12 hour, 1~14day 0 hour, 14day 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour, 19~21day 0 hour, 21day 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour

  3. Cmax,ss of D352(Part 1)

    The maximum D352 concentration in steady-state

    Time frame: 1~7day 0 hour, 7day 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hour, 19~21day 0 hour, 21day 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hour

  4. Cmax,ss of D794(Part 2)

    The maximum D794 concentration in steady-state

    Time frame: 1day -24 hour~-12 hour, 1~14day 0 hour, 14day 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour, 19~21day 0 hour, 21day 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hour

07

Study locations

1 site
  • H Plus Yangji Hospital
    Gwanak-gu, Seoul 08779, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jan 2025, 1 month.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 1 month is below that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2024
First posted
Jan 6, 2025
StartActual
Nov 27, 2024
Primary completionActual
Jan 24, 2025
CompletionActual
Feb 3, 2025
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06758661
Responsible party
Sponsor
First posted
Jan 6, 2025
Start date
Nov 27, 2024
Primary completion
Jan 24, 2025
Completion
Feb 3, 2025
Last update
May 21, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion